About Raven Biotechnologies
Raven Biotechnologies is a company based in San Francisco (United States) founded in 1998 was acquired by MacroGenics in July 2008.. Raven Biotechnologies has raised $91.98 million across 3 funding rounds from investors including MacroGenics, Biogen and Tekla Capital Management. Raven Biotechnologies operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$91.98 M (USD)
in 3 rounds
-
Latest Funding Round
$48.3 M (USD), Series D
Oct 12, 2005
-
Investors
MacroGenics
& 6 more
-
Employee Count
Employee Count
-
Acquired by
MacroGenics
(Jul 17, 2008)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Raven Biotechnologies
Raven Biotechnologies has successfully raised a total of $91.98M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $48.3 million completed in October 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series D — $48.3M
-
First Round
First Round
(11 Apr 2003)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2005 | Amount | Series D - Raven Biotechnologies | Valuation |
investors |
|
| Nov, 2004 | Amount | Series C - Raven Biotechnologies | Valuation |
investors |
|
| Apr, 2003 | Amount | Series C - Raven Biotechnologies | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Raven Biotechnologies
Raven Biotechnologies has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include MacroGenics, Biogen and Tekla Capital Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is invested in AI, energy, and various sectors.
|
Founded Year | Domain | Location | |
|
VC firm that focuses on early stage investments in the US
|
Founded Year | Domain | Location | |
|
Private equity investments are backed by a single-family office firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Raven Biotechnologies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Raven Biotechnologies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Raven Biotechnologies Comparisons
Competitors of Raven Biotechnologies
Raven Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Raven Biotechnologies
When was Raven Biotechnologies founded?
Raven Biotechnologies was founded in 1998 and raised its 1st funding round 5 years after it was founded.
Where is Raven Biotechnologies located?
Raven Biotechnologies is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Raven Biotechnologies a funded company?
Raven Biotechnologies is a funded company, having raised a total of $91.98M across 3 funding rounds to date. The company's 1st funding round was a Series C of $42.86M, raised on Apr 11, 2003.
What does Raven Biotechnologies do?
Raven Biotechnologies was focused on the development of monoclonal antibody (MAb) therapies cancer. Its approach was based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines. Its lead product RAV12, targets adenocarcinomas and was in clinical development for the treatment of gastrointestinal and other cancers. It also claims to have identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer.
Who are the top competitors of Raven Biotechnologies?
Raven Biotechnologies's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Raven Biotechnologies's investors?
Raven Biotechnologies has 7 investors. Key investors include MacroGenics, Biogen, Tekla Capital Management, Mitsubishi UFJ Capital, and Integra Ventures.